Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jan;131(1):48-52.
doi: 10.1046/j.1365-2249.2003.02031.x.

Nicotinamide is a potent inhibitor of proinflammatory cytokines

Affiliations

Nicotinamide is a potent inhibitor of proinflammatory cytokines

J S Ungerstedt et al. Clin Exp Immunol. 2003 Jan.

Abstract

The present study investigates the modulating effects of nicotinamide on the cytokine response to endotoxin. In an in vitro model of endotoxaemia, human whole blood was stimulated for two hours with endotoxin at 1 ng/ml, achieving high levels of the proinflammatory cytokines IL-1 beta, IL-6, IL-8 and TNF alpha. When coincubating whole blood, endotoxin and the vitamin B3 derivative nicotinamide, all four cytokines measured were inhibited in a dose dependent manner. Inhibition was observed already at a nicotinamide concentration of 2 mmol/l. At a concentration of 40 mmol/l, the IL-1 beta, IL-6 and TNF alpha responses were reduced by more than 95% and the IL-8 levels reduced by 85%. Endotoxin stimulation activates poly(ADP-ribose)polymerase (PARP), a nuclear DNA repair enzyme. It has been hypothesized that the anti-inflammatory properties of nicotinamide are due to PARP inhibition. In the present study, the endotoxin induced PARP activation was dose dependently decreased with 4-40 mmol/l nicotinamide or 4-100 micro mol/l 6(5H) phenanthridinone, a specific PARP inhibitor. 6(5H)phenanthridinone however, failed to inhibit the proinflammatory cytokines. Thus, the mechanism behind the cytokine inhibition in our model seems not to be due to PARP inhibition. In conclusion, the present study could not only confirm previous reports of a down-regulatory effect on TNFalpha, but demonstrates that nicotinamide is a potent modulator of several proinflammatory cytokines. These findings demonstrate that nicotinamide has a potent immunomodulatory effect in vitro, and may have great potential for treatment of human inflammatory disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a) IL-6, (b) TNFα,(c) IL-1β and (d) IL-8 responses to a two hour incubation of whole blood with 1 ng/ml endotoxin at 37°C with 5% CO2. A dose dependent down-regulation by 2–100 mmol/l nicotinamide is observed. Box plots are shown with 5th & 95th percentiles. *statistically significant P < 0·05 compared to initial levels.
Fig. 2
Fig. 2
PARP activity was inhibited by nicotinamide. PARP activity induced by 1 ng/ml endotoxin was set to 100%. Arrows indicate samples incubated for two hours without endotoxin or nicotinamide. …… negative control for each experiment. • and ○ symbolize the two healthy volunteers.
Fig. 3
Fig. 3
IL-1β, IL-6, IL-8 and TNFα responses to 1 ng/ml endotoxin in whole blood, into which different amounts of the specific PARP inhibitor 6(5H)phenanthridinone had been added to five different tubes. n= 2, each line represents one healthy volunteer. Left y-axis: □ TNFα, ○ IL-8, ▪ IL-6; right side y-axis • IL-1β.

References

    1. Schumann RR, Latz E. Lipopolysaccharide-binding protein. Chem Immunol. 2000;74:42–60. - PubMed
    1. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3. - PubMed
    1. Verbon A, Dekkers PE, ten Hove T, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166:3599–605. - PubMed
    1. Muller JM, Ziegler-Heitbrock HWL, Bauerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology. 1993;187:233–56. - PubMed
    1. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol. 1990;55:157–70. - PubMed

Publication types

MeSH terms